Male contraception startup Secures $92.5 Million in Latest Series B Funding Round

Male contraception startup secured $92.5 million in its latest Series B, adding another data point to the Legal, Regulatory & Compliance funding market.

Male contraception startup Raises $92.5 million in Funding

Male contraception startup is a LegalTech company focused on sup­port a Phase 3 study of a male con­tra­cep­tive dubbed NES/T.

Investors Behind the Funding

The round was backed by undisclosed investors. Funding Intelligence tracks this investor activity alongside sector momentum, co-investor patterns, and recent comparable raises.

Company Profile and Market Context

Male contraception startup operates in Legal, Regulatory & Compliance. Male contraception startup's Series B round shows investors are still backing legaltech platforms with real scale narratives. At $93M, the deal suggests buyers want category leaders that can turn AI, automation, or workflow leverage into durable enterprise demand.

Strategic Use of Funds

sup­port a Phase 3 study of a male con­tra­cep­tive dubbed NES/T

Looking Ahead

Male contraception startup closes $92.5M Series B; Novartis bets on actinium in Phase 3

Source reference: original announcement/article.